This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lamont, J. M. Articles by Ellison, D. W. Search for Related Content PubMed PubMed Citation Articles by Lamont, J. M. Articles by Ellison, D. W.

Combined Histopathological and Molecular Cytogenetic Stratification of Medulloblastoma Patients

Northern Institute for Cancer Research, University of Newcastle, Newcastle-upon-Tyne, United Kingdom

This study examined the utility of stratifying children with medulloblastomas by a combination of refined histopathological classification and molecular cytogenetic evaluation.

Detailed histopathological classification of tumors from a cohort of patients (n = 87) composed mainly of children entered into the International Society of Pediatric Oncology (SIOP)/United Kingdom Children’s Cancer Study Group PNET3 trial (n = 65), included identification of the large cell/anaplastic phenotype. Fluorescence in situ hybridization was used to detect chromosome 17 abnormalities, losses of 9q22 and 10q24, and amplification of the MYCC and MYCN oncogenes.

The large cell/anaplastic phenotype, which was present in 20% of medulloblastomas, emerged as an independent prognostic indicator. Loss of 17p13.3 (38% of medulloblastomas) was found across all of the histopathological variants, whereas MYCC/MYCN amplification (6%/8% of medulloblastomas) was significantly associated with the large cell/anaplastic phenotype. Both of these genetic abnormalities emerged as prognostic indicators. Loss of 9q22 was associated with the nodular/desmoplastic medulloblastoma variant, whereas loss of 10q24 was found in all of the variants. Together with metastatic tumor at presentation, the large cell/anaplastic phenotype, 17p13.3 loss, or high-frequency MYC amplification defined a high-risk group of children whose outcome was significantly (P = 0.0002) poorer than a low-risk group without these tumor characteristics.

Combined evaluation of novel histopathological features and molecular cytogenetic abnormalities promises to allow stratification of patients with medulloblastoma, such that those likely to be cured will be spared the side effects of maximal therapy, which can be targeted at those with aggressive disease.

This article has been cited by other articles:

				B Pizer and S Clifford Medulloblastoma: new insights into biology and treatment Arch. Dis. Child. Ed. Pract., October 1, 2008; 93(5): 137 - 144. [Full Text] [PDF]

				T. de Haas, N. Hasselt, D. Troost, H. Caron, M. Popovic, L. Zadravec-Zaletel, W. Grajkowska, M. Perek, M.-C. Osterheld, D. Ellison, et al. Molecular Risk Stratification of Medulloblastoma Patients Based on Immunohistochemical Analysis of MYC, LDHB, and CCNB1 Expression Clin. Cancer Res., July 1, 2008; 14(13): 4154 - 4160. [Abstract] [Full Text] [PDF]

				S. Rutkowski, A. von Bueren, K. von Hoff, W. Hartmann, T. Shalaby, F. Deinlein, M. Warmuth-Metz, N. Soerensen, A. Emser, U. Bode, et al. Prognostic Relevance of Clinical and Biological Risk Factors in Childhood Medulloblastoma: Results of Patients Treated in the Prospective Multicenter Trial HIT'91 Clin. Cancer Res., May 1, 2007; 13(9): 2651 - 2657. [Abstract] [Full Text] [PDF]

				R. J. Packer, A. Gajjar, G. Vezina, L. Rorke-Adams, P. C. Burger, P. L. Robertson, L. Bayer, D. LaFond, B. R. Donahue, M. H. Marymont, et al. Phase III Study of Craniospinal Radiation Therapy Followed by Adjuvant Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma J. Clin. Oncol., September 1, 2006; 24(25): 4202 - 4208. [Abstract] [Full Text] [PDF]

				L. A. Garraway and W. R. Sellers From integrated genomics to tumor lineage dependency. Cancer Res., March 1, 2006; 66(5): 2506 - 2508. [Abstract] [Full Text] [PDF]

				D. Stearns, A. Chaudhry, T. W. Abel, P. C. Burger, C. V. Dang, and C. G. Eberhart c-Myc Overexpression Causes Anaplasia in Medulloblastoma Cancer Res., January 15, 2006; 66(2): 673 - 681. [Abstract] [Full Text] [PDF]

				F. Mendrzyk, B. Radlwimmer, S. Joos, F. Kokocinski, A. Benner, D. E. Stange, K. Neben, H. Fiegler, N. P. Carter, G. Reifenberger, et al. Genomic and Protein Expression Profiling Identifies CDK6 As Novel Independent Prognostic Marker in Medulloblastoma J. Clin. Oncol., December 1, 2005; 23(34): 8853 - 8862. [Abstract] [Full Text] [PDF]

				D. W. Ellison, O. E. Onilude, J. C. Lindsey, M. E. Lusher, C. L. Weston, R. E. Taylor, A. D. Pearson, and S. C. Clifford {beta}-Catenin Status Predicts a Favorable Outcome in Childhood Medulloblastoma: The United Kingdom Children's Cancer Study Group Brain Tumour Committee J. Clin. Oncol., November 1, 2005; 23(31): 7951 - 7957. [Abstract] [Full Text] [PDF]

				B. Argenti, R. Gallo, L. Di Marcotullio, E. Ferretti, M. Napolitano, S. Canterini, E. De Smaele, A. Greco, M. T. Fiorenza, M. Maroder, et al. Hedgehog Antagonist RENKCTD11 Regulates Proliferation and Apoptosis of Developing Granule Cell Progenitors J. Neurosci., September 7, 2005; 25(36): 8338 - 8346. [Abstract] [Full Text] [PDF]

				A. Huang, C. S.W. Ho, R. Ponzielli, D. Barsyte-Lovejoy, E. Bouffet, D. Picard, C. E. Hawkins, and L. Z. Penn Identification of a Novel c-Myc Protein Interactor, JPO2, with Transforming Activity in Medulloblastoma Cells Cancer Res., July 1, 2005; 65(13): 5607 - 5619. [Abstract] [Full Text] [PDF]